30.08.2022 BB BIOTECH AG  CH0038389992

DGAP-News: BB BIOTECH AG: Moderna was just the beginning


DGAP-News: BB BIOTECH AG / Key word(s): Market Report
BB BIOTECH AG: Moderna was just the beginning

30.08.2022 / 11:00
The issuer is solely responsible for the content of this announcement.

Market commentary, August 30, 2022

Dr. Daniel Koller, Head Investment Management Team, BB Biotech at Bellevue Asset Management

Moderna was just the beginning

RNA-based drugs will revolutionize the application of gene therapy to treat a growing number of diseases and disorders during the coming years.

Alnylam, a stock in BB Biotech's portfolio, made its biggest one-day gain since the company went public in June of 2004. Alnylam shares were marked up 60%, reaching a new all-time high, in reaction to the publication of promising data from a pivotal trial of patisiran, an active substance the company is testing on patients with transthyretin amyloid cardiomyopathy. ATTR cardiomyopathy (ATTR-CM) is a rare inherited disease which is characterized by a buildup of faulty amyloid deposits, causing irreversible damage to the heart and nerves, as well other organs or tissues. The life expectancy of a typical patient is less than five years from diagnosis.

Alnylam will present detailed trial results at a medical conference in September and plans to file for regulatory approval in this indication by the end of the year.

The euphoric reaction of financial markets to this news reflects consensus expectations that patisiran will deliver billions in annual peak sales in this indication. Patisiran was already approved for the treatment of the polyneuropathy of ATTR amyloidosis four years ago and is sold under the brand name Onpattro. Alnylam reported annual sales of USD 475 mn from this drug in 2021. Some 50 000 individuals worldwide are affected by ATTR amyloidosis, and Onpattro could be prescribed to treat an additional 300 000 adults with ATTR-CM.

Commercial breakthrough a reality

Alnylam is considered to be one of the most promising takeover candidates in the biotech industry today. The company is marketing four authorized products and will present pivotal clinical trial data on five pipeline candidates by the end of 2023, including Phase III data for fitusiran, an investigational RNA interference treatment for people with hemophilia that Alnylam is developing in collaboration with Sanofi. However, the most compelling takeover argument from an acquirer's perspective is Alnylam's status as a pioneer and market leader in the field of small interfering RNA (siRNA) technology. This is a therapeutic approach that utilizes double-stranded RNA molecules to block the mechanisms of target proteins that have been identified as triggers for certain diseases. Simply put, messenger RNA (mRNA), i.e., the genetic blueprint encoding disease-causing proteins, is effectively suppressed to inhibit the production of those proteins.

RNAi (RNA interference) is a natural biological process for silencing or inhibiting gene expression. siRNAs are one class of RNAi mediators. Antisense technology is a related field where scientists are utilizing short single-stranded nucleic acids, or antisense oligonucleotides, to detect and eliminate disease-causing proteins. Ionis Pharma, a US biotech company, is a pioneer in the field of antisense that has been a core fixture of BB Biotech's portfolio for years. Messenger RNA, or mRNA for short, on the other hand, is a different therapeutic approach that instructs cells to make certain proteins. mRNA technology achieved a major commercial breakthrough with the development and marketing approval of COVID-19 vaccines in less than a year’s time. These mRNA vaccines train the body's immune system to detect viral proteins and develop an effective response without actually getting sick. The two COVID-19 vaccines developed by Moderna and Pfizer/Biontech were crucial in containing the coronavirus pandemic.

RNA technology enters a new chapter

BB Biotech recognized the medical potential of RNA technology early on. There are a total of four RNA-focused companies, including two core shareholdings, Moderna and Ionis, in its portfolio with an aggregate weighting of around 25%. The double-digit price gains of these companies in response to the breakthrough at Alnylam also helped BB Biotech's share price to gain 10% during the same period. In addition to Alnylam’s gains, the value of our stake in Wave Life Sciences rose by 50%. This markup was triggered by the company’s announcement that clinical trials of drugs in genome-editing therapies would begin next year.

Looking ahead to the next few years, we expect RNA-based drugs to enter a new market phase. Under the assumption, of course, that the later-stage testing is likewise successful, the range of potential applications for RNA-based therapeutics would grow to include diseases that affect large patient populations, for example cardiovascular diseases, metabolic disorders, cancer and organ fibrosis. Innovative products that make it to the market will generate billions in revenues.



Dr. Daniel Koller has been with Bellevue Asset Management since 2004 as a Portfolio Manager and was appointed Head of Investment Management Team BB Biotech AG in 2010. From 2001 to 2004 he was an investment manager at equity4life Asset Management AG and from 2000 to 2001 an equity analyst at UBS Warburg. He studied biochemistry at the Swiss Federal Institute of Technology in Zurich (ETH) and earned his doctorate in biotechnology at the ETH and Cytos Biotechnology AG, Zurich.



For further information:

Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00
Dr. Silvia Schanz, [email protected]
Maria-Grazia Alderuccio, [email protected]
Claude Mikkelsen, [email protected]

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00
Tanja Chicherio, [email protected]




Company profile
BB Biotech AG is an investment company registered in Schaffhausen/Switzerland and listed on the Swiss, German and Italian stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. BB Biotech relies on the long-standing experience of its distinguished Board of Directors and the investment research skills of the experienced investment management team of Bellevue Asset Management AG when making its investment decisions.


This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.

30.08.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Schwertstrasse 6
8200 Schaffhausen
Phone: +41 52 624 08 45
E-mail: [email protected]
Internet: www.bbbiotech.ch
ISIN: CH0038389992
Listed: Regulated Market in Frankfurt (Prime Standard); Mailand, SIX
EQS News ID: 1430689

End of News DGAP News Service

1430689  30.08.2022 


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023
Umsatzerlöse1 624,17 5,13 669,48 683,90 0,00 1,28 0,57
EBITDA1,2 588,33 -418,21 624,04 637,31 -390,46 -361,02 -222,29
EBITDA-Marge3 94,26 -8.152,24 93,21 93,19 0,00 -28.204,69
EBIT1,4 588,33 -418,21 624,04 637,31 -390,46 -361,02 -222,29
EBIT-Marge5 94,26 -8.152,24 93,21 93,19 0,00 -28.204,69 -38.998,25
Jahresüberschuss1 587,80 -418,27 622,84 637,24 -390,53 -362,83 -222,41
Netto-Marge6 94,17 -8.153,41 93,03 93,18 0,00 -28.346,09 -39.019,30
Cashflow1,7 225,26 95,66 197,69 241,97 -91,44 234,37 234,97
Ergebnis je Aktie8 10,62 -7,55 11,24 11,51 -7,05 -6,59 -4,05
Dividende8 2,85 2,68 3,20 3,32 3,67 2,88 2,58
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

BB Biotech
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0NFN3 45,250 Kaufen 2.506,85
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
32,32 5,42 5,89 114,27
1,05 10,67 4.397,98 -11,28
Dividende '22 in € Dividende '23 in € Div.-Rendite '23
in %
2,88 2,10 4,64 19.03.2025
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
26.04.2024 26.07.2024 25.10.2024 21.02.2025
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
8,22% 3,54% -0,98% -6,70%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu BB BIOTECH AG  ISIN: CH0038389992 können Sie bei EQS abrufen

Biotechnologie , A0NFN3 , BBZA , XETR:BBZA